The individualized prescription model is what makes compounding the right pathway here
In January 2025, the ITC issued a notice stating it was not going to review the summary determination order but sought further comments on public interest and remedy
BPC-157 is not FDA-approved for any medical condition, including soft-tissue injury, gut healing, pain, inflammation, anti-aging, or performance enhancement
Water Intake, Water Balance, and the Elusive Daily Water Requirement
Monitor for symptoms such as dizziness, lightheadedness, or fainting if taking medications such as ACE inhibitors (e.g., ramipril), calcium channel blockers (e.g., amlodipine), or beta-blockers (e.g., bisoprolol)
The benefits of specific GLP-1 medicationsincluding reduced cardiovascular events, improved kidney outcomes, and better quality of lifeare substantial for many patients